|Vanda Pharmaceuticals, Inc.|
2200 Pennsylvania Avenue NW
United States - Map
Vanda Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development and commercialization of pharmaceutical products. Its product portfolio includes HETLIOZ, a product for the treatment of Non-24-Hour Sleep-Wake Disorder; Fanapt, a product for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor antagonist. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
|Vanda Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Sep 1, 2014 is 10. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 10; Compensation: 8.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Mihael H. Polymeropoulos M.D.,
Founder, Chief Exec. Officer, Pres and Director
|Mr. James Patrick Kelly ,
Chief Financial Officer, Principal Accounting Officer, Sr. VP, Treasurer and Sec.
|Dr. Paolo Baroldi M.D., Ph.D.,
Chief Medical Officer and Sr. VP
|Mr. Vincent J. Milano ,
Director, Chairman of Compensation Committee and Member of Audit Committee
|Mr. Gunther Birznieks ,
VP of Bus. Devel.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|